Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?

Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?

BackgroundHead and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression. Therefore, several agents targeting the pathways that mediate angiogenesis have been developed....

Full description

Bibliographic Details
Main Authors: Aini Hyytiäinen, Wafa Wahbi, Otto Väyrynen, Kauko Saarilahti, Peeter Karihtala, Tuula Salo, Ahmed Al-Samadi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
anti-angiogenesis
head and neck cancer
therapy
endostatin
bevacizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.683570/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.683570/full

Similar Items